Subcutaneous Atezolizumab: A Jab Without a Benefit

Clin Pharmacol Drug Dev. 2022 Jan;11(1):134-135. doi: 10.1002/cpdd.1061. Epub 2021 Dec 23.

Authors

Cody J Peer¹, Sara M Zimmerman¹, William D Figg¹, Daniel A Goldstein^{2

3

4}, Mark J Ratain⁵

Affiliations

¹ Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
² Tel Aviv University, Tel Aviv, Israel.
³ Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
⁴ Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
⁵ Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.

PMID: 34951144
DOI: 10.1002/cpdd.1061

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans
Janus Kinase 2*

Substances

Antibodies, Monoclonal, Humanized
atezolizumab
Janus Kinase 2

Grants and funding